Details of Metabolite

General Information of MET (ID: META00652)
Name Cidofovir
Synonyms   Click to Show/Hide Synonyms of This Metabolite
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate; (S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-HPMPC; 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine; 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine; CDV; Cidofovir; Cidofovir anhydrous; Cidofovir sodium; Cidofovir, (+-)-isomer; Cidofovir, (R)-isomer; Cidofovir, sodium salt; HPMPC; Vistide; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
Source Drug
Structure Type   Pyrimidines and pyrimidine derivatives  (Click to Show/Hide the Complete Structure Type Hierarchy)
Organoheterocyclic compounds
Diazines
Pyrimidines and pyrimidine derivatives
PubChem CID
60613
HMDB ID
HMDB0014513
Formula
C8H14N3O6P
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60613"></iframe>
3D MOL 2D MOL
  Click to Show/Hide the Molecular/Functional Data (External Links/Property/Function) of This Metabolite
KEGG ID
C06909
DrugBank ID
DB00369
ChEBI ID
3696
ChemSpider ID
54636
Physicochemical Properties Molecular Weight 279.19 Topological Polar Surface Area 146
XlogP -3.6 Complexity 417
Heavy Atom Count 18 Rotatable Bond Count 6
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 6
Function
Cidofovir is only found in individuals that have used or taken this drug. It is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. [Wikipedia]Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.
Regulatory Network
Full List of Protein(s) Regulating This Metabolite
      Organic ion transporter (OIT)
            Organic anion transporter 1 (OAT1) Click to Show/Hide the Full List of Regulating Pair(s):   6 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair (1) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (F438A) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (F438A) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
               Regulating Pair (2) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (F438Y) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (F438Y) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
               Regulating Pair (3) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (K431A) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (K431A) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
               Regulating Pair (4) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (K431R) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (K431R) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
               Regulating Pair (5) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (Y230A) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (Y230A) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
               Regulating Pair (6) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (Y230F) of SLC22A6
                      Induced Change Cidofovir concentration: decrease (FC = 0.25)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (Y230F) of SLC22A6 leads to the decrease of cidofovir levels compared with control group.
References
1 A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J Biol Chem. 2006 Dec 8;281(49):38071-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.